Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05908734 · ClinicalTrials.gov registry record · Phase 1

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
71
Enrollment target
20
Study locations

NCT05908734: Active Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

NCT05908734 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 71 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05908734, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
71 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).

Primary Outcome

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Amivantamab
  • DRUG Cetrelimab

Study Locations (20)

Other

  • Fundacao Pio XII - Barretos
  • Cetus Oncologia - Belo Horizonte
  • PERSONAL Oncologia de Precisao e Personalizada - Belo Horizonte
  • CIONC Centro Integrado de Oncologia de Curitiba - Curitiba
  • Hospital do Cancer de Londrina - Londrina
  • Hospital Nossa Senhora da Conceicao S A - Porto Alegre
  • Hospital Santa Izabel Santa Casa de Misericordia da Bahia - Salvador
  • Fundacao Antonio Prudente A C Camargo Cancer Center - São Paulo
  • European Institute of Oncology - Milan
  • ASST Grande Ospedale Metropolitano Niguarda - Milan
  • Aou San Luigi Gonzaga - Orbassano
  • Centro Ricerche Cliniche di Verona S r l - Verona
  • University Malaya Medical Centre - Kuala Lumpur

California

  • City of Hope - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • Cancer and Blood Specialty Clinic - Los Alamitos

Oregon

  • Providence Portland Medical Center - Portland
  • Providence Oncology and Hematology Care Clinic Westside - Portland

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2023-05-18
Est. Completion 2027-03-31
Phase Phase 1
Janssen Research & Development

593 total trials

What the registry record for NCT05908734 still lists

NCT05908734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Amivantamab is the first listed.

NCT05908734 names 20 study sites across 5 states, led by Other, California, Oregon.

Frequently Asked Questions

What is clinical trial NCT05908734 about?

NCT05908734 is a clinical study titled "A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer". The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination a...

What is the current status of trial NCT05908734?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2023-05-18. Estimated completion is 2027-03-31.

What conditions does trial NCT05908734 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT05908734?

The interventions under investigation include: Amivantamab (DRUG), Cetrelimab (DRUG).

Who is sponsoring clinical trial NCT05908734?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05908734 being conducted?

This trial has 20 study locations across California, Oregon, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05908734's enrollment target sits among peer trials

71 81st of 130 higher than 49 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05908734, the US trial registry maintained by the National Library of Medicine. NCT05908734 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.